- 10 minutes
- News in EU 2020 | European PRRS Research Awards
Winners of the 2020 European PRRS Research Award announced
- Boehringer Ingelheim recognizes scientific excellence by awarding three research proposals with a funding of 25,000 euro each
- The company sponsored the annual European PRRS Awards for the seventh time
Ingelheim, Germany, October 7, 2020 – Boehringer Ingelheim honors three winning research proposals with a funding of 25,000 euro each as part of the European PRRS Awards to encourage further development of practical methods for controlling PRRS (Porcine Reproductive and Respiratory Syndrome), and to recognize scientific excellence in this field. Furthermore, the company offers a valuable opportunity for interaction and academic exchange among swine researchers and veterinary practitioners. The winners were selected by an independent expert panel.
PRRS continues to be a highly prevalent disease(1) in European pigs, causing economic losses(2) through its negative effects on reproduction and growth as well as by clinical illness.
The European PRRS Research Award review board is chaired by Enric Mateu (Universidad Autònoma de Barcelona) with members from across swine practice and academia: Helle Jessen (Danvet), Andrea Ladinig (Vetmeduni Vienna), Giovanbattista Danilo Guadagnini (PigVet), Gyula Balka (Veterinary Medicine Budapest) ), Michele Drigo (University of Padova), and Torsten Pabst (Tierarztpraxis Dr. Pabst).
In 2020, the company has sponsored the annual European PRRS Research Award for the seventh time already. The winners of this year’s European PRRS Research Award, as selected by the review board after careful evaluation, are:
- Biosecurity and management impact on PRRS status and economical profit: statistical process control after evaluation and improvement (Ramis Vidal, Universidad de Murcia – Spain)
- PRRSV1 genetic recombination in swine herds: an emerging risk or hype (Erhard van d. Vries, Royal GD – The Netherlands)
- Impact of weaning procedures on PRRSV in the nursery (Pia R. Heiselberg, HyoVet – Denmark)
The prizes will be awarded to the winners at the fifth European PRRSpective taking place in Bern, Switzerland, in 2021.
Boehringer Ingelheim Animal Health
The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. Across the globe, our 10,000 employees are dedicated to delivering value through innovation, thus enhancing the well-being of both.
Respect for animals, humans and the environment is at the heart of what we do. We develop solutions and provide services to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.
Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 countries. For more information visit: www.boehringer-ingelheim.com/animal-health/overview.
Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com.
Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
References
(2) https://www.ncbi.nlm.nih.gov/pubmed/28606362